TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02805088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalographic recordings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalographic recordings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalographic recordings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical evaluation of symptoms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical evaluation of symptoms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical evaluation of symptoms
Study: NCT04048967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional development
Description: professional development of preschool staff
Study: NCT03115801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation & immunotherapy
Description: Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
Study: NCT00151411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Intervention
Description: A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
Study: NCT02033980

Intervention type: DEVICE
Group type: OTHER
Intervention: NBI
Description: All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
Study: NCT03508531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP Block
Description: A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OSTAP block
Description: The bilateral OSTAP will be performed at the end of the surgery. A total of 40 ml local anesthetic mixture (Bupivacaine and lidocaine) will be injected bilaterally with interfascial plane between the external oblique and transversus abdominis muscles

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study: NCT01696409

Intervention type: DIETARY_SUPPLEMENT
Intervention: 400 IU vitamin D3
Description: Take 400 IU once/day for 2 months

Intervention type: DIETARY_SUPPLEMENT
Intervention: 2000 IU vitamin D3
Description: 2000 IU vitamin D3 once/day for 2 months
Study: NCT03508531

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study: NCT03593161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humor therapy
Description: Clown visits
Study: NCT03549273

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glizigen® + Ocoxin-Viusid®
Description: * Glizigen® spray, topical use, 2 times a day for 6 months with an interruption for 2 months at the end of the third month.~* Ocoxin®-Viusid® 60 ml daily (1 vial every 12 hours) by oral route for 8 months, preferably administered after breakfast and lunch, without interruption.
Study: NCT01362400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPI 504 plus Docetaxel
Description: 450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Docetaxel
Description: 450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)
Study: NCT04536415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir Phosphate 75 mg capsules
Description: Capsules, 75 mg, single, oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamiflu capsules 75 mg
Description: Capsules, 75 mg, single, oral dose
Study: NCT03711071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workshop ICE training
Description: The workshop includes training in communication skills in relation to evidence based medicine.
Study: NCT00893594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan with naprosyn
Description: Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
Study: NCT03267095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy sessions .
Description: In this intervention songs compose by the therapist will be use for the study. The songs included the target word .The target words will be selecte from functional vocabularies that typically developing 3years old children can use effectively in everyday interactions.The general criteria for vocabulary words included: names of familiar objects and persons, functional action words such as words for social control , and emotional words . Inherent musical structures structures and organized musical patterns in the songs will be provide .The patients will reflect on the music therapy activity as singing the song together.
Study: NCT01936649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AdreView (Iobenguane I 123 Injection)
Description: AdreView 10 mCi as a single i.v administration
Study: NCT01858584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrotuss
Description: Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~* Infants weighing \<5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~* Infants weighing\> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day
Study: NCT02963467

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cigarette
Description: smoking 4 conventional cigarettes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cigarette
Description: smoking 4 conventional cigarettes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: dummy cigarette
Description: smoking a dummy cigarette
Study: NCT02050048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of Lactated Ringer's (LR) Solution
Description: Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~* initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~* LR fluid infusion during the procedure at 5 cc/kg/hr~* Post-procedure bolus of 20 cc/kg over 90 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Lactated Ringer's (LR) Solution
Description: Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~* initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~* LR fluid infusion during the procedure at 5 cc/kg/hr~* Post-procedure bolus of 20 cc/kg over 90 minutes
Study: NCT03510143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neoveil (Polyglycolic Acid Mesh)
Description: Apply the Neoveil (Polyglycolic Acid Mesh) in the neck node dissection area in thyroid cancer surgery.
Study: NCT01996319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVA149
Description: QVA149 (110/50 µg) once a day via Breezhaler® device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVA149
Description: QVA149 (110/50 µg) once a day via Breezhaler® device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo once a day via Breezhaler® device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo once a day via Breezhaler® device
Study: NCT04367701

Intervention type: DIAGNOSTIC_TEST
Intervention: Hemolysis
Description: Authors measured free plasma hemoglobin concentration in gram

Intervention type: DIAGNOSTIC_TEST
Intervention: Hemolysis
Description: Authors measured free plasma hemoglobin concentration in gram
Study: NCT02445378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aromatherapy and Essential Oils
Description: Undergo aromatherapy and essential oils

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aromatherapy and Essential Oils
Description: Undergo aromatherapy and essential oils

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Undergo placebo intervention using rose water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Undergo placebo intervention using rose water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00674908

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Easy Five
Description: Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
Study: NCT03756233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.
Study: NCT00548431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: Standard dose 25 mg/m\^2/day. Can be increased up to 75 mg/m\^2/day if the myelosuppression is acceptable (ANC\>0.5 T-count \>50)
Study: NCT02445378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01858584

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: thickened milk
Description: Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
Study: NCT02419755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
Study: NCT01780558

Intervention type: OTHER
Group type: OTHER
Intervention: natural cycles
Description: the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
Study: NCT02419755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-L-Asparaginase
Description: Given by intravenous (IV) or intramuscular (IM) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia L-Asparaginase
Description: To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or intravenously (IV).
Study: NCT01780558

Intervention type: DRUG
Group type: OTHER
Intervention: estradiol and progesterone
Description: oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
Study: NCT03616080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: soccer play program
Description: once a week for an hour of a soccer program for 8 weeks
Study: NCT00117338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Pbo for a study approximately 120 minutes in duration
Study: NCT03312946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modellata
Description: treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks.
Study: NCT02616029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablets administered orally once daily
Study: NCT04450355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam 80mg/day
Description: continuous nefopam infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: continuous normal saline infusion
Study: NCT02021123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin 100mg single dose iv
Description: Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
Study: NCT02527876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: High Intensity Interval Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity
Description: Moderate Intensity Training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Control
Description: Delayed Control

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: FitBit Flex
Description: Use to measure increase in Physical Activity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit Flex
Description: Use to measure increase in Physical Activity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit Flex
Description: Use to measure increase in Physical Activity
Study: NCT02806778

Intervention type: OTHER
Intervention: BIS Monitor-guided sedation
Description: The patients enrolled in the study will undergo BIS Monitor-guided sedation. Standard BIS Monitor will be used for the procedure to monitor the depth of sedation.

Intervention type: OTHER
Intervention: Jugular bulb catheter
Description: Jugular bulb catheter will be implanted in the patients enrolled in the study.
Study: NCT01782599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual nicotine patch and electronic cigarette
Study: NCT00003210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02711345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: ERK Inhibitor
Study: NCT02419755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given intravenously (IV).
Study: NCT02203097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial pressure of CO2 at the end of an exhaled breath
Description: Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
Study: NCT03894904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papaverine
Description: 0.12 mg/mL papaverine administered as soon as the arterial catheter is placed and secured, and 0.12 mg/mL papaverine administered one hour after initial dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
Study: NCT04807660

Intervention type: OTHER
Intervention: middle ear fluid sample
Description: middle ear fluid sample for each enrrolled children
Study: NCT02472561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit Physical Activity Monitor
Description: Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Glucometer
Description: Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Blood Pressure
Description: Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.